Supervised Rosuvastatin Rechallenge

The patient is an adult with elevated cholesterol levels and reported difficulty tolerating prior statin treatment, in the setting of a broader medical history documented at intake.

Referral for face-to-face cardiology assessment may be valuable, especially with a clinician experienced in preventive cardiovascular care, lipid disorders, or complex cholesterol management.

A supervised rosuvastatin rechallenge may be considered. One conservative approach would be to begin with 2.5 mg to 5 mg once per week.

If tolerated, the regimen may be advanced slowly over time. A reasonable sequence would include once-weekly dosing, then twice-weekly dosing, then alternate-day dosing, then daily therapy.

After daily use is tolerated, the dose may be increased stepwise to 10 mg daily, 20 mg daily, and 40 mg daily, while continuing the highest regimen the patient can tolerate safely.

Lipid testing should be repeated after approximately three months, or after a stable treatment pattern has been achieved.

For primary prevention of clinical ASCVD, an LDL cholesterol goal below 100 mg/dL may be appropriate.

For patients with established coronary artery disease, including prior myocardial infarction or coronary artery bypass grafting, an LDL cholesterol goal below 70 mg/dL, or lower in selected high-risk circumstances, may be appropriate.

If LDL cholesterol remains above goal despite the maximally tolerated statin regimen, ezetimibe may be added if tolerated.

If muscle symptoms recur, other potential causes should be reviewed. Creatine kinase testing is appropriate when myalgias, weakness, or other muscle-related symptoms develop.

In a patient with previous statin-associated myalgias or myopathy, creatine kinase monitoring may be considered after each increase in dose or dosing frequency.

If symptoms develop during treatment escalation, the regimen may be reduced to the last tolerated dose or schedule. Ongoing monitoring should assess both symptom recurrence and relevant laboratory abnormalities.

Familial hypercholesterolemia should be considered, particularly if LDL cholesterol remains at or above 190 mg/dL after reversible contributors, including thyroid dysfunction, have been addressed.

Formal diagnostic criteria for familial hypercholesterolemia may then be applied, including the Dutch Lipid Clinic Network Criteria.

It may also be reasonable to begin documentation for insurance authorization of additional lipid-lowering therapy. Options may include PCSK9 inhibitors such as Repatha or Praluent, as well as bempedoic acid-based therapy such as Nexletol or Nexlizet.

Coverage may depend on documentation of prior statin trials and intolerance; beginning a cautious rosuvastatin rechallenge while preparing authorization materials may be clinically practical.

Advanced lipid-lowering therapy may require payer review and may not be approved immediately. During that interval, a low-dose, low-frequency rosuvastatin strategy may still offer benefit.

If symptoms persist despite holding statin therapy, non-statin causes should be evaluated. A temporary treatment pause of approximately two weeks may help clarify whether symptoms are related to statin exposure.

If myalgias occur with elevated creatine kinase and no alternative explanation is identified, statin therapy should be held while further assessment is completed.

Begin rosuvastatin 5 mg by mouth once weekly. If tolerated at approximately two-week intervals, increase sequentially to twice weekly, then every other day, then daily dosing.

If daily dosing is tolerated, advance to 10 mg daily, then 20 mg daily, then 40 mg daily, maintaining the highest tolerated regimen from this sequence.

At the same time, begin preparing prior-authorization documentation for advanced lipid-lowering therapy when clinically appropriate.